PAI
XERS icon

Palo Alto Investors’s Xeris Biopharma Holdings XERS Stock Holding History

Palo Alto Investors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$606K Buy
+104,410
New +$692K 0.09% 46

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Palo Alto Investors's XERS Position: Q1 2026 in Review

Palo Alto Investors opened a new position in Xeris Biopharma Holdings (XERS) in Q1 2026: 104,410 shares worth $606K. The stake represents 0.09% of the portfolio and ranks #46 among its holdings.

237 funds tracked by Wall St. Rank hold XERS as of Q1 2026.

  • Palo Alto Investors held 104,410 shares of Xeris Biopharma Holdings worth $606K as of Q1 2026.
  • Xeris Biopharma Holdings was a new Palo Alto Investors position in Q1 2026.
  • Xeris Biopharma Holdings made up 0.09% of Palo Alto Investors's portfolio in Q1 2026, its #46 holding.
  • 237 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.